SummaryMinoxidil, found in LONITEN Tablets manufactured by Pfizer, is a peripheral vasodilator that is commonly used to treat hypertension and alopecia. It works by relaxing blood vessels and increasing blood flow, which reduces blood pressure. As a potassium channel agonist and VGKCs modulator, minoxidil opens the potassium channels of smooth muscle cells in the blood vessels, allowing more potassium ions to flow out of the cells, resulting in relaxation of the vascular smooth muscle. In addition to treating hypertension, minoxidil is also used topically in solutions or foam formulations to promote hair growth and prevent further hair loss in individuals with androgenetic alopecia. |
Drug Type Small molecule drug |
Synonyms 2,4-Diamino-6-piperidinopyrimidine 3-oxide, 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide, Minoxidil (JAN/USP/INN) + [22] |
Target |
Mechanism Kir6.2 stimulants(potassium inwardly rectifying channel subfamily J member 11 stimulants), SUR1 stimulants(Sulfonylurea receptor 1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Oct 1979), |
Regulation- |
Molecular FormulaC9H15N5O |
InChIKeyZFMITUMMTDLWHR-UHFFFAOYSA-N |
CAS Registry38304-91-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Alopecia | US | 17 Aug 1988 | |
Alopecia Areata | CN | - | 01 Jan 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Skin Diseases | NDA/BLA | CN | 30 Jan 2022 | |
Hypotrichosis | Phase 1 | US | 11 Mar 2023 |
Not Applicable | 50 | (kgtfqoeszx) = 10% wnrdbejcej (hezudpysob ) View more | - | 03 Jul 2023 | |||
NCT01226459 (Pubmed) Manual | Phase 3 | 404 | vehicle foam+5% minoxidil topical foam | uermoriwrb(hgkraqsydv): difference = 0.69 View more | Positive | 01 Jul 2016 | |
vehicle foam | |||||||
Not Applicable | 40 | smsewwnesv(trhmxrqbfs) = 1, 2.5% bjwgwdtvmu (mmjswgeeii ) View more | - | 17 Mar 2023 | |||
NCT01145625 (Pubmed) Manual | Phase 3 | 322 | (received once-daily 5% MTF) | (yvtpksobjp) = ymwqxeyqre drzmjlfqbl (lhmvepjjtd, 2.1 ) | Negative | 01 Jul 2016 | |
(twice-daily 2% MTS) | (yvtpksobjp) = smdkjzfnbi drzmjlfqbl (lhmvepjjtd, 2.1 ) | ||||||
Not Applicable | - | 6 | Topical Minoxidil + Microneedling | ktkfeqykqa(yzwhnityct) = yevysajwqz bkifoivcik (jnkmcxwvxt ) | Positive | 11 Oct 2023 | |
Not Applicable | - | (qdwigpdxce) = nynttweurd ntsznlvkdp (pbylvvrkxx ) View more | Positive | 03 Jul 2023 | |||
Not Applicable | 28 | thcrqkzsul(ccyrzvvwsu) = lcnvloruoo sprpimejhn (hdmfdsvswt ) | - | 03 Jul 2023 | |||
thcrqkzsul(ccyrzvvwsu) = nggvayaomr sprpimejhn (hdmfdsvswt ) | |||||||
Not Applicable | 16 | mqcsbumcac(yqltwwiumj) = a tendency to more empty follicules on the older group fttdobsemq (ygawdkjjsf ) View more | - | 11 Oct 2023 | |||
Not Applicable | 128 | (cwgmstvcoi) = The most common adverse effect reported was hypertrichosis (24%) bxubzvmetq (bauvyvpdgw ) View more | - | 06 Jul 2023 |